277 related articles for article (PubMed ID: 15660288)
1. Reactive arthritis following BCG immunotherapy for bladder carcinoma.
Tinazzi E; Ficarra V; Simeoni S; Peterlana D; Lunardi C
Clin Rheumatol; 2005 Aug; 24(4):425-7. PubMed ID: 15660288
[TBL] [Abstract][Full Text] [Related]
2. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.
Tinazzi E; Ficarra V; Simeoni S; Artibani W; Lunardi C
Rheumatol Int; 2006 Apr; 26(6):481-8. PubMed ID: 16220289
[TBL] [Abstract][Full Text] [Related]
3. Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations.
Ng KL; Chua CB
Asian J Surg; 2017 Apr; 40(2):163-165. PubMed ID: 25183290
[TBL] [Abstract][Full Text] [Related]
4. Reactive arthritis after the intravesical instillation of BCG.
Macía Villa C; Sifuentes Giraldo W; Boteanu A; González Lanza M; Bachiller Corral J
Reumatol Clin; 2012; 8(5):284-6. PubMed ID: 22377450
[TBL] [Abstract][Full Text] [Related]
5. [Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report].
Shiba M; Fujii T; Takatera H
Hinyokika Kiyo; 2003 Oct; 49(10):599-601. PubMed ID: 14655604
[TBL] [Abstract][Full Text] [Related]
6. [Dactilitis and oligoarthritis after BCG immunotherapy in a patient affected by bladder cancer].
Manzini CU; Bernini L; Elkhaldi N; Mascia MT; Ferri C
Reumatismo; 2006; 58(3):230-2. PubMed ID: 17013441
[TBL] [Abstract][Full Text] [Related]
7. Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer.
Onur O; Celiker R
Clin Rheumatol; 1999; 18(1):74-6. PubMed ID: 10088958
[TBL] [Abstract][Full Text] [Related]
8. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.
Rintala E; Jauhiainen K; Alfthan O; Hansson E; Juusela H; Kanerva K; Korhonen H; Permi J; Sotarauta M; Vaalasti T
Eur Urol; 1991; 20(1):19-25. PubMed ID: 1743226
[TBL] [Abstract][Full Text] [Related]
9. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
[No Abstract] [Full Text] [Related]
10. [Clinical experience with BCG immune prevention in superficial bladder cancer].
Bach D; Romics I; Rüssel C
Urologe A; 1992 Sep; 31(5):296-301. PubMed ID: 1302409
[TBL] [Abstract][Full Text] [Related]
11. Reactive arthritis associated with Bacillus Calmette-Guerin immunotherapy for carcinoma of the bladder: a report of two cases.
Jawad AS; Kahn L; Copland RF; Henderson DC; Abdul-Ahad AK
Br J Rheumatol; 1993 Nov; 32(11):1018-20. PubMed ID: 8220923
[No Abstract] [Full Text] [Related]
12. [Reactive Arthritis during the Second Course of Intravesical BCG Therapy Requiring Administration of Methotrexate : A Case Report].
Ikeuchi R; Sunada T; Yoshikawa T; Yoshida T; Tabuchi Y; Kajita Y; Segawa T
Hinyokika Kiyo; 2017 Aug; 63(8):329-332. PubMed ID: 28889718
[TBL] [Abstract][Full Text] [Related]
13. Reiter's syndrome following intravesical BCG immunotherapy.
Hogarth MB; Thomas S; Seifert MH; Tariq SM
Postgrad Med J; 2000 Dec; 76(902):791-3. PubMed ID: 11085772
[TBL] [Abstract][Full Text] [Related]
14. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy.
Aust TR; Massey JA
Int J Urol; 2005 Oct; 12(10):920-1. PubMed ID: 16323989
[TBL] [Abstract][Full Text] [Related]
15. [Reiter's syndrome following intravesical instillation of Bacillus Calmette-Guerin].
Okamoto K; Hamano T; Kawaguchi T
Hinyokika Kiyo; 2010 Feb; 56(2):111-3. PubMed ID: 20185998
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment.
Paterson DL; Patel A
Aust N Z J Surg; 1998 May; 68(5):340-4. PubMed ID: 9631906
[TBL] [Abstract][Full Text] [Related]
17. Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature.
Bernini L; Manzini CU; Giuggioli D; Sebastiani M; Ferri C
Autoimmun Rev; 2013 Oct; 12(12):1150-9. PubMed ID: 23816569
[TBL] [Abstract][Full Text] [Related]
18. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
19. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
Saint F; Salomon L; Quintela R; Cicco A; Hoznek A; Abbou CC; Chopin DK
Eur Urol; 2003 Apr; 43(4):351-60; discussion 360-1. PubMed ID: 12667715
[TBL] [Abstract][Full Text] [Related]
20. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
